In the latest session, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $5.18 up 1.97% from its previous closing price of $5.08. In other words, the price has increased by $+0.10 from its previous closing price. On the day, 1182368 shares were traded.
Ratios:
For a deeper understanding of Aurinia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 06 ’24 when Greenleaf Peter sold 126,981 shares for $5.60 per share. The transaction valued at 711,094 led to the insider holds 1,522,114 shares of the business.
Robertson Stephen P. sold 57,745 shares of AUPH for $323,372 on Mar 06 ’24. The EVP, General Counsel now owns 443,824 shares after completing the transaction at $5.60 per share. On Mar 06 ’24, another insider, Donley Matthew Maxwell, who serves as the EVP, Ops & Strategy of the company, sold 40,665 shares for $5.51 each. As a result, the insider received 224,064 and left with 584,072 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 734.66M and an Enterprise Value of 481.78M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 1.97. Its current Enterprise Value per Revenue stands at 2.74 whereas that against EBITDA is -7.64.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.38, which has changed by -47.46% over the last 52 weeks, in comparison to a change of 26.95% over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $4.85. The 50-Day Moving Average of the stock is 6.27, while the 200-Day Moving Average is calculated to be 8.29.
Shares Statistics:
For the past three months, AUPH has traded an average of 2.41M shares per day and 1.5M over the past ten days. A total of 143.83M shares are outstanding, with a floating share count of 127.86M. Insiders hold about 11.59% of the company’s shares, while institutions hold 36.63% stake in the company. Shares short for AUPH as of Mar 15, 2024 were 10.65M with a Short Ratio of 4.42, compared to 16.85M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.36% and a Short% of Float of 7.39%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.39, with 6 analysts recommending between $0.83 and -$0.14.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $47.45M this quarter.It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
